2.63

1.72% -0.04

Abcellera Biologics Inc (ABCL)

Überblick Nachrichten Preisverlauf Optionskette Financials Warum fällt ABCL? Forum Prognose

Schlusskurs vom Vortag:

$2.67

Offen:

$2.66

24-Stunden-Volumen:

319.44K

Relative Volume:

0.15

Marktkapitalisierung:

$788.63M

Einnahmen:

$38.03M

Nettoeinkommen (Verlust:

$-146.40M

KGV:

-5.8444

EPS:

-0.45

Netto-Cashflow:

$-121.38M

1W Leistung:

-4.93%

1M Leistung:

-5.27%

6M Leistung:

-31.84%

1J Leistung:

-39.54%

1-Tages-Spanne:

$2.61

$2.7075

1-Wochen-Bereich:

$2.57

$2.76

52-Wochen-Spanne:

$2.335

$6.055

Abcellera Biologics Inc Stock (ABCL) Company Profile

Firmenname

Abcellera Biologics Inc

Sektor

Healthcare (1195)

Branche

Biotechnology (683)

Telefon

(604) 559-9005

Adresse

2215 YUKON STREET, VANCOUVER

Mitarbeiter

586

Twitter

Nächster Verdiensttermin

2024-11-18

Neueste SEC-Einreichungen

ABCL's Discussions on Twitter

Vergleichen Sie ABCL mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
ABCL	2.625	788.63M	38.03M	-146.40M	-121.38M	-0.45
VRTX	445.82	115.74B	10.63B	-479.80M	-1.35B	13.33
REGN	741.34	81.65B	13.85B	4.65B	3.32B	35.06
ARGX	589.04	34.86B	1.86B	-40.29M	-1.28B	-4.16
ALNY	248.89	32.09B	2.09B	-332.26M	16.06M	-4.14
BNTX	102.89	24.49B	3.30B	-501.07M	1.03B	11.54

Abcellera Biologics Inc Stock (ABCL) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2024-08-20	Herabstufung	The Benchmark Company	Buy → Hold
2024-02-22	Hochstufung	The Benchmark Company	Hold → Buy
2023-12-05	Eingeleitet	KeyBanc Capital Markets	Overweight
2023-11-06	Herabstufung	The Benchmark Company	Buy → Hold
2023-10-13	Fortgesetzt	Piper Sandler	Overweight
2023-02-28	Eingeleitet	Cowen	Outperform
2022-12-15	Eingeleitet	Goldman	Buy
2022-11-16	Eingeleitet	Truist	Buy
2021-12-21	Eingeleitet	The Benchmark Company	Buy
2021-11-19	Eingeleitet	Piper Sandler	Overweight
2021-01-05	Eingeleitet	BMO Capital Markets	Outperform
2021-01-05	Eingeleitet	Berenberg	Buy
2021-01-05	Eingeleitet	Credit Suisse	Outperform
2021-01-05	Eingeleitet	SVB Leerink	Outperform
2021-01-05	Eingeleitet	Stifel	Buy

Alle ansehen

Abcellera Biologics Inc Aktie (ABCL) Neueste Nachrichten

Nov 20, 2024

ABCL (AbCellera Biologics) Goodwill-to-Asset : 0.03 (As of Sep. 2024) - GuruFocus.com

Nov 20, 2024

ABCL (AbCellera Biologics) EBIT per Share : $-1.00 (TTM As of Sep. 2024) - GuruFocus.com

Nov 20, 2024

Nov 19, 2024

GSA Capital Partners LLP Boosts Stock Position in AbCellera Biologics Inc. (NASDAQ:ABCL) - MarketBeat

Nov 19, 2024

Nov 13, 2024

AbCellera Biologics Inc. (NASDAQ:ABCL) Shares Sold by Baillie Gifford & Co. - MarketBeat

Nov 13, 2024

Nov 11, 2024

AbCellera Biologics (NASDAQ:ABCL) Sees Strong Trading VolumeShould You Buy? - MarketBeat

Nov 11, 2024

Nov 08, 2024

AbCellera Presents Data on Applications of T-Cell Engager Platform at SITC 2024 - Business Wire

Nov 07, 2024

AbCellera Biologics Inc. (NASDAQ:ABCL) Just Reported And Analysts Have Been Cutting Their Estimates - Simply Wall St

Nov 07, 2024

Leerink Partnrs Has Pessimistic View of ABCL FY2024 Earnings - MarketBeat

Nov 07, 2024

AbCellera Unveils Breakthrough T-Cell Platform Data, Shows Promise in Cancer Treatment | ABCL Stock News - StockTitan

Nov 07, 2024

Nov 06, 2024

AbCellera Biologics Third Quarter 2024 Earnings: Misses Expectations - Yahoo Finance

Nov 06, 2024

Nov 05, 2024

AbCellera Biologics (NASDAQ:ABCL) Given "Hold" Rating at Benchmark - MarketBeat

Nov 05, 2024

AbCellera Biologics (NASDAQ:ABCL) Given "Buy" Rating at Stifel Nicolaus - MarketBeat

Nov 05, 2024

AbCellera Biologics (NASDAQ:ABCL) Shares Gap Down After Earnings Miss - MarketBeat

Nov 05, 2024

AbCellera Biologics (NASDAQ:ABCL) Posts Quarterly Earnings Results, Misses Expectations By $0.03 EPS - MarketBeat

Nov 05, 2024

AbCellera stock price target cut, keeps Outperform on strategic pivot By Investing.com - Investing.com UK

Nov 05, 2024

AbCellera Biologics Inc. (NASDAQ:ABCL) Q3 2024 Earnings Call Transcript - Insider Monkey

Nov 05, 2024